Pasithea Financial Statements From 2010 to 2025

KTTAW Stock  USD 0.02  0  9.89%   
Pasithea Therapeutics financial statements provide useful quarterly and yearly information to potential Pasithea Therapeutics Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pasithea Therapeutics financial statements helps investors assess Pasithea Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pasithea Therapeutics' valuation are summarized below:
Pasithea Therapeutics Corp does not presently have any trending fundamental ratios for analysis.
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Pasithea Therapeutics Corp Company Return On Asset Analysis

Pasithea Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Return On Asset

 = 

Net Income

Total Assets

More About Return On Asset | All Equity Analysis

Current Pasithea Therapeutics Return On Asset

    
  -0.41  
Most of Pasithea Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pasithea Therapeutics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Competition

Based on the latest financial disclosure, Pasithea Therapeutics Corp has a Return On Asset of -0.4093. This is 95.32% lower than that of the Biotechnology sector and 98.27% lower than that of the Health Care industry. The return on asset for all United States stocks is 192.36% higher than that of the company.

Pasithea Therapeutics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pasithea Therapeutics's current stock value. Our valuation model uses many indicators to compare Pasithea Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pasithea Therapeutics competition to find correlations between indicators driving Pasithea Therapeutics's intrinsic value. More Info.
Pasithea Therapeutics Corp is rated second overall in return on equity category among its peers. It also is rated second overall in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Pasithea Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida. Pasithea Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.